Patents by Inventor Ludvig Sollid

Ludvig Sollid has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Detection of gluten-specific t-cells
    Patent number: 10677794
    Abstract: The present invention relates to compositions and methods for visualizing disease-specific T-cells. In particular, the present invention relates to compositions and methods for use in the diagnosis, monitoring of progression, monitoring of response to therapy, and selection of patients for therapy of autoimmune diseases characterized by selective expansion of disease-specific effector memory T-cells.
    Type: Grant
    Filed: May 14, 2014
    Date of Patent: June 9, 2020
    Assignee: OSLO UNIVERSITETSSYKEHUS HF
    Inventors: Ludvig Sollid, Shuo-wang Qiao, Asbjorn Christophersen, Knut E. A. Lundin
  • DETECTION OF GLUTEN-SPECIFIC T-CELLS
    Publication number: 20160109443
    Abstract: The present invention relates to compositions and methods for visualizing disease-specific T-cells. In particular, the present invention relates to compositions and methods for use in the diagnosis, monitoring of progression, monitoring of response to therapy, and selection of patients for therapy of autoimmune diseases characterized by selective expansion of disease-specific effector memory T-cells.
    Type: Application
    Filed: May 14, 2014
    Publication date: April 21, 2016
    Inventors: Ludvig Sollid, Shuo-wang Qiao, Asbjorn Christophersen, Knut E.A. Lundin
  • Drug therapy for Celiac Sprue
    Publication number: 20070161572
    Abstract: Celiac Sprue and/or dermatitis herpetiformis are treated by interfering with HLA binding of immunogenic gluten peptides. The antigenicity of gluten oligopeptides and the ill effects caused by an immune response thereto are decreased by administration of an HLA-binding peptide inhibitor. Such inhibitors are analogs of immunogenic gluten peptides and (i) retain the ability to bind tightly to HLA molecules; (ii) retain the proteolytic stability of these peptides; but (iii) are unable to activate disease-specific T cells.
    Type: Application
    Filed: March 2, 2007
    Publication date: July 12, 2007
    Inventors: Ludvig Sollid, Chaitan Khosla, Hanne Quarsten, Chu-Young Kim
  • Prolyl endopeptidase mediated destruction of T cell epitopes in whole gluten
    Publication number: 20060286601
    Abstract: Celiac Sprue and/or dermatitis herpetiformis are treated by interfering with HLA binding of immunogenic gluten peptides. The antigenicity of gluten oligopeptides and the ill effects caused by an immune response thereto are decreased by administration of an HLA-binding peptide inhibitor. Such inhibitors are analogs of immunogenic gluten peptides and (i) retain the ability to bind tightly to HLA molecules; (ii) retain the proteolytic stability of these peptides; but (iii) are unable to activate disease-specific T cells.
    Type: Application
    Filed: April 26, 2005
    Publication date: December 21, 2006
    Inventors: Thomas Marti, Oyvind Molberg, Ludvig Sollid
  • Drug therapy for celiac sprue
    Publication number: 20050256054
    Abstract: Celiac Sprue and/or dermatitis herpetiformis arc treated by interfering with HLA binding of immunogenic gluten peptides. The antigenicity of gluten oligopeptides and the ill effects caused by an immune response thereto are decreased by administration of an HLA-binding peptide inhibitor. Such inhibitors are analogs of immunogenic gluten peptides and (i) retain the ability to bind tightly to HLA molecules; (ii) retain the protcolytic stability of these peptides; but (iii) are unable to activate disease-specific T cells.
    Type: Application
    Filed: May 14, 2003
    Publication date: November 17, 2005
    Inventors: Ludvig Sollid, Chaitan Khosla, Hanne Quarsten, Chu-Young Kim